Gene Therapy with LNPs, Possibilities, Limitations, New Strategies
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 72
Special Issue Editors
Interests: nanomedicine; gene therapy; glioblastoma multiforme; targeted delivery; enzyme delivery
Interests: drug delivery; nanomedicine; brain delivery; microfluidic production; gene therapy; lipid nanoparticles; targeted delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to present this Special Issue on the use of LNPs for gene therapy, entitled “Gene Therapy with LNPs: Possibilities, Limitations, And New Strategies”.
In recent years, the utilization of lipidic nanoparticles for gene therapy has been widely investigated after the success of the COVID-19 vaccine. Notwithstanding the incredible opportunities offered by the application of lipid nanoparticles in gene therapy, several issues need to be addressed. In fact, the use of mRNA or siRNA might seem advantageous due to their cytoplasmic target, but these molecules are highly unstable. DNA, on the other hand, exhibits greater stability against formulation stresses; however, it requires nuclear delivery, which poses extensive difficulties.
In this Special Issue, we plan to collect research articles and reviews that demonstrate how researchers are addressing the current limitations of gene therapy with LNPs. The scope of this Special Issue includes, but is not limited to, the following:
- Novel LNP formulative strategies;
- Innovations or new insights regarding the lipidic composition of LNPs;
- Analysis of the intracellular trafficking of LNPs and their payload;
- Delivery of mRNA, siRNA, ASOs, pDNA, as well as other genome editing tools such as Cas9;
- Innovative strategies for genome editing;
- Advanced characterization methods for LNP morphology.
Dr. Jason Thomas Duskey
Dr. Ilaria Ottonelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene therapy
- lipid nanoparticles
- nucleic acid delivery
- nuclear targeted LNPs
- microfluidic production of LNPs
